期刊
GEBURTSHILFE UND FRAUENHEILKUNDE
卷 81, 期 5, 页码 526-538出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1464-0953
关键词
early breast cancer; prevention; treatment; prognosis; immunotherapy; digital medicine
资金
- Hexal
- Pfizer
- Lilly
- Novartis
- Daiichi-Sankyo
- Merrimack
- Eisai
- PRAEGNANT network - Pfizer
- MSD
- AstraZeneca
- onkowissen.de
This review provides an overview of the latest evidence on breast cancer prevention and treatment for early-stage patients, including the significance of panel genes, endocrine efficacy, and adjuvant therapies such as CDK4/6 inhibitors. It also discusses the use of immune checkpoint inhibitors in improving pathologic complete response rates for TNBC patients, highlighting the importance of understanding quality of life and side effects in treatment decision-making.
This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据